To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
In their presentation at the 48th ONS Congress, in San Antonio, Texas, Kathy Waitman DNP, APN-BC, AOCNP and Shaunna Kersten CNS, MSN, ANP identified the best imaging modalities based on common oncologic...
Researchers determined the predictive value of urine point-of-care tenofovir antibody test and compared the results against self-reported PrEP use and TFV-diphosphate levels in dried blood spots. Their...
Researchers evaluated the response rate of gemcitabine in patients with platinum-resistant ovarian cancer given at a low dosage. Their research was presented at the Hematology/Oncology Pharmacy...
This COVID-19 roundup includes coverage of the FDA’s amendment to its emergency use authorization of the Pfizer-BioNTech booster for pediatric patients, acute myocardial infection deaths rose during omicron...
The results of a recent study presented at the 2023 Hematology/Oncology Pharmacy Association annual conference suggest health care providers should be vigilant about the overutilization of potentially...
The FDA has approved a treatment for Friedreich ataxia after the results of randomized, placebo-controlled study indicate a strong effectiveness in treatment.
Researchers evaluated the impact an intensified dose of dolutegravir had on patients living with HIV. Their research was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023...
Researchers set out to determine the percentage of people in the United States with type 2 diabetes who meet the recommended criteria to use GLP-1 receptor agonists and SGLT-2 inhibitors as well as patients...
In a recent study presented at the Hematology/Oncology Pharmacy Association annual conference, researchers examined the use of opioids in patients with head and neck squamous cell carcinoma while undergoing...
